Bei Akademie registrieren
DTIL, US74019P2074

Precision BioSciences stock has a November 2, 2026 earnings date

Published on 10/15/2026 at 21:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Second-quarter loss reached USD 1.26 per share on August 6, 2026. Precision BioSciences stock costs EUR 5.50 on October 15, 2026 at 9:20 p.m. CEST.

Earnings date and quarterly loss

  • Precision BioSciences is estimated to report third-quarter results on November 2, 2026.
  • The company reported a USD 1.26 adjusted loss per share for the second quarter on August 6, 2026.
  • Precision BioSciences stock costs EUR 5.50 at Lang & Schwarz on October 15, 2026 at 9:20 p.m. CEST.
  • Market capitalization stood at USD 170.0 million on October 15, 2026.
DTIL, US74019P2074, Illustration mit AI erstellt.
DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences is estimated to report third-quarter results on November 2, 2026, according to MarketBeat. The company reported a USD 1.26 loss per share for the second quarter on August 6, 2026, versus a USD 0.80 consensus loss, the same source said. Precision BioSciences was trading at EUR 5.50 at Lang & Schwarz on October 15, 2026 at 9:20 p.m. CEST.

Second-quarter loss missed expectations

The quarterly result gives the calendar date a sharper financial backdrop. The USD 1.26 loss per share exceeded the USD 0.80 consensus loss by USD 0.46, while MarketBeat reported a negative net margin of 96.73 percent for the quarter. The figures describe the second quarter of 2026, not the upcoming third-quarter period.

Cash supports clinical programs

Precision BioSciences reported USD 86.1 million in cash and cash equivalents at June 30, 2026. Operating cash flow was negative USD 13.4 million during the second quarter, according to the standardized quarterly figures. The company is developing gene-editing therapies through its ARCUS platform, with programs addressing chronic hepatitis B and Duchenne muscular dystrophy.

What comes next on November 2?

MarketBeat lists November 2, 2026, as the estimated third-quarter reporting date, before the market opens. Its estimate calls for a USD 0.85 loss per share and USD 1.38 million in revenue for the quarter. The source also lists a conference call for November 6, 2026, at 9:30 a.m. ET.

Comparison with peers

The following figures are dated October 15, 2026.

DTIL (Nasdaq, USD): P/E minus 2.20, market capitalization USD 170.0 million
CRSP (Nasdaq, USD): daily change plus 3.66 percent, P/E minus 10.93, market capitalization USD 5.0 billion
EDIT (Nasdaq, USD): daily change plus 7.27 percent, P/E minus 3.25, market capitalization USD 374.0 million

Price and market value

Precision BioSciences had a market capitalization of USD 170.0 million on October 15, 2026. Its 52-week range was USD 3.53 to USD 9.62 on the same date, placing the company between the yearly low and high. The Nasdaq-listed biotechnology company had an average trading volume of 269,714 shares, while volume stood at 178,776 shares on October 15, 2026.

The next scheduled date is the estimated November 2, 2026 third-quarter report. For investors, the key contrast is the near-term reporting date against the second-quarter loss of USD 1.26 per share and the company's USD 86.1 million cash balance at June 30, 2026.

Precision BioSciences was trading at EUR 5.50 at Lang & Schwarz on October 15, 2026 at 9:20 p.m. CEST.

Precision BioSciences market data

  • Company: Precision BioSciences, Inc.
  • ISIN: US74019P2074
  • Ticker: DTIL
  • Primary exchange: Nasdaq
  • Price Lang & Schwarz (as of October 15, 2026, 9:20 p.m. CEST): EUR 5.50
  • Market capitalization: USD 170.0 million (as of October 15, 2026)
  • 52-week range: USD 3.53-9.62 (as of October 15, 2026)
  • Sector / Industry: Healthcare / Biotechnology

Market context: Market report Nasdaq Composite.

The latest company developments and market context are collected on the Precision BioSciences stock topic page.

Disclaimer...
en | US74019P2074 | DTIL | boerse | 70332778 | bgmi